AGRX
$0.55
Agile Therap
($.05)
(7.91%)
AGRX
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.14)
Revenue:  $1.78 Mil
Tuesday
Feb 1
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AGRX reports earnings?
Beat
Meet
Miss

Where is AGRX's stock price going from here?
Up
Flat
Down
Stock chart of AGRX
Analysts
Summary of analysts' recommendations for AGRX
Score
Grade
Pivots
Resistance
$0.64
$0.62
$0.59

$0.56

Support
$0.53
$0.51
$0.47
Tweet
Growth
Description
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Peers
Vertex PharmaceuticalsUltragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalMerck & Co.ZoetisEli LillyBristol-Myers SquibbPfizerInterCept